Jefferies Stays on Sidelines with Myriad (MYGN) after DNA Ruling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BofA/Merrill Lynch Downgrades Myriad Genetics (MYGN) to Neutral
June 14, 2013 6:46 AM EDTBofA/Merrill Lynch downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $32.01 yesterday, with a 52 week range of $22.02-$38.27.... More
RBC Capital Downgrades Myriad Genetics (MYGN) to Sector Perform
June 14, 2013 6:45 AM EDTRBC Capital downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Sector Perform with a price target of $32.00 (unchanged).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For... More
JMP Securities Upgrades Myriad Genetics (MYGN) to Market Outperform
June 14, 2013 6:44 AM EDTJMP Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Market Outperform with a price target of $48.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For... More
Leerink Swann Downgrades Myriad Genetics (MYGN) to Market Perform
June 13, 2013 2:44 PM EDTLeerink Swann downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform with a price target of $39.00. Analyst Dan Leonard thinks investor focus will now turn to competition and the stock has no place to go but down.
"Following the Supreme Court's... More
Piper Jaffray Boosts Myriad Genetics (MYGN) Price Target to $49
June 13, 2013 1:50 PM EDTPiper Jaffray today maintained an Overweight rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to a Street-high $49.00 (from $39.00).
For an analyst ratings summary and ratings history on Myriad Genetics click... More
Myriad (MYGN) Issues Response to Supreme Court Decision on Gene Patent
June 13, 2013 10:55 AM EDTMyriad Genetics (Nasdaq: MYGN) posted the following response to the U.S. Supreme Court ruling made earlier on its Facebook page:
"The Supreme Court has... More
Myriad Genetics (MYGN) trading paused/halted due to limit up, limit down
June 13, 2013 10:26 AM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) trading paused due to limit up, limit down.... More
Gene Patent Limited by High Court in Mixed Ruling for Myriad (MYGN)
June 13, 2013 10:24 AM EDT(Updated - June 13, 2013 10:33 AM EDT)
Gene patent limited by high court in mixed ruling for Myriad Genetics, Inc. (NASDAQ: MYGN), according to Bloomberg headlines.
For the U.S. Supreme Court document (pdf format), click here.
Myriad is up 9 percent on the session.... More
